Cefepime (4Th Gen) Injectable (Iv/Im) Suppliers & Bulk Manufacturers
Available Forms: Injectable (IV/IM)
Available Strengths: 1 g, 2 g, 4 g per vial
Reference Brands: Maxipime(US & EU)
Category:
Antibiotics
Cefepime inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, causing bacterial lysis. It is effective against multi-drug resistant gram-negative bacteria, including Pseudomonas. Benefits include rapid bacterial eradication, broad-spectrum activity, and use in severe infections like pneumonia and sepsis, especially in hospital settings for critical cases.
Cefepime (4th Gen) Injectable (IV/IM) is available in Injectable (IV/IM)
and strengths such as 1 g, 2 g, 4 g per vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Cefepime (4th Gen) Injectable (IV/IM) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Cefepime (4th Gen) Injectable (IV/IM) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cefepime IV injection is approved in the EU and US for treating severe bacterial infections, including pneumonia, sepsis, and febrile neutropenia. In the EU, brands like Maxipime are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, quality assurance, and pharmacovigilance plans, for approval and continuous safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for cefepime injection, ensuring adherence to European and US standards for safe, effective treatment of serious infections.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing